T he elucidation of the reactions le.iding to both the release of arachidonic acid from membranebound phospholipids and its subsequent metabolic conversion into potent, biologically active lipids are landmark discoveries in the areas of physiology and inflammation. Historically, early investigations in this field were directed at isolating und characterizing the diverse metabolites of the cyclooxygenation of arachidonit acid. Kurzockand Lieb,' Goldblatt,^ and von Euler' contributed seminal observations regarding the biologic activity of an acidic lipid believed to be synthesized by the prostate gland, hence the term prostaglandin. Later, Bergstrom and co-workers'*^ demonstrated that prostaglandins represent a spectrum oi related lipids with a similar chemical structure. The major impetus to study the biochemical role and pharmacologit manipulation of arachidonic acid metabolism, with regard to inflammation, was provided by Vane,'' with the observation that aspirin and aspirinlike drugs could suppress prostagl.indin synthesis and regulate inflammatory reactions. The foundation for subsequent work concerning produc ts of the lipoxygenase pathway was laid by Feldberg and Kellawayî n 19^8. In tbese early experiments, they demonstrated that the perfusate of cobra venom-treated lungs con tained both a lysolecithin-like compound and a compound that generated a smooth muscle contracting factor termed slow reacting substance" (SRS). Nearly 30 years later, these same SRS-type compounds were found to play a key role in immediate hypersensitivity reactions, especially asthma." SRS of anaphylaxis (SRS-A) is usually referred to as an immunologically released SRS and now is known to consist oi leukotriene C4, D4. and E4. The structural work and complete chemical In addition to the studies by these Nobel laureates, numerous investigators have demonstrated the ability oi arachidonic acid metabolites to participate in the regulation of diverse physiologic systems. This is truly exemplified by the key rote these ubiquitous fatty acids play in dictating the function of cells that are involved in acute and chronic immune reactions. Products from both the cyclooxygenase and lipoxygenase pathway {Fig. 1) are known to be synthesized during immuneinflammatory responses and can influence the outcome of various phlogistic episodes. There is little doubt that LTB4 and many of the hydroxylated eicosatetraenoic acids (HETEs) are important in acute-neutrophil-mediated reactions. These lipoxygenase products appear to play a central rote in the initiation and maintenance of acute inflammation by causing leukocyte chemotaxis," aggregation,'^ lysosom.il enzyme release,'^ and the production of oxygen metabolites.'"' Conversely, specific cyclooxygenase-derived metabolites (PGE, and PCIjJ have been shown to suppress many of the above leukocytic functions.''^ '"Thus, the products of the two major pathways of arachidonic acid metabolism have been hypothesized to function in a yin-yang manner as the inflammatory reaction is initiated and eventually resolved. Although the current literature concerning arachidonate metabolites in neutrophil-mediated reaction is voluminous, an exhaustive review examining the participation of these various lipids in acute inflammation is beyond the scope of this article. The goal of this review is to summarize and expand our current understanding of the biochemical, biologic and clinical aspects of arachidonic acid metabolic products in macrophage-and lymphocyte-mediated reactions.
Metabolism of Arachidonic Acid by Mononuclear Phdgocytic Cells
The importance of arachidonic acid metabolites synthesized by mononuclear phagocytes is suggested by the bigh percentage of this fatty acid found esterified in the number two position of membrane phospbolipids. Arachidonic acid was found to constitute approximately 25% of all esterified membrane fatty acids in various mononuclear phagocytic cell preparations,'"''' while neutrophil membranes contained less than 3% esterified arachidonic acid.-'" Phosphoiipid analysis of macrophage membranes indicates that the majority of arachidonic acid is found at position two of phosphatidylcholine.'' The functional importance of this particular phosphoiipid as a reservoir of macrophage aracbldonic acid is shown clearly by the reduction in arachidonic acid metabolites by macrophages treated with inhibitors of phosphatidylcholine synthesis," and the dramatic loss of arachidonic acid from phosphatidylcholine with a concomitant appearance of metabolites by stimulated macrophages. It is important to note that the mobilization of arachidonic acid is dependent upon the activation of pbospholipases by specific receptor-ligand interactions.^^ This concept is critical, since investigations have demonstrated that phospholipases may be maintained as separate pools within the macrophage.''' One pool appears to be associated with intracellular lysosomes and triggered by a phagocytic stimulus and an additional pool appears to be associated with the plasmalemma and activated by membrane perturbation. In additional studies,^^' the activation of phospholipase and the mobilization of different pools of substrate arachidonic acid have been shown to result in different types of metabolic products. Membrane perturbants, such as phorbol esters^" and lipopolysaccharide,'^^ selectively stimulated the cyclooxygenation of arachidonic acid, while zymosan triggered both metabolic pathways.
As detailed above, the metabolism of arachidonic acid occurs by two major routes. The major metabolites synthesized by macrophages via the cyclo-oxygenase pathway are prostaglandin E2 (PGE2) and prostacyclin (PGI2), while thromboxane TXA2 (and its stable metabotite, TXB2) and prostaglandin F2J have also been identified.-^^ Macrophages have a significant ability to metabolize arachidonic acid through the lipoxygenase pathway with the concomitant synthesis of mono- HETEs and leukotrienes. Although mono-HETEs (predominantly 12-HETE) appear to be the most abundant of the macrophage-derived lipoxygenase products, the leukotrienes are the best understood. Various cultured macrophage preparations have been shown to synthesize a number of biologic ally active lipids, including conjugated Irienes.^^ '" While speculations abound concerning the clinical role these leukotrienes play in human disease, save for certain types of asthma, the exact role of these lipoxygenase products remains enigmatic.
There is little doubl that mononuclear phagocytic cells possess a unique capability to metabolize arachidonic acid to numerous metabolic end points. This prolific metabolic capacity of macrophages has lead numerous investigators to study those factors that dictate the various facets of macrophage arachidonic acid metabolism. The quantitative and qualitative aspects of metabolite formation clearly is a function of both the exogenous stimulus and the state of macrophage activation. The latter is defined by a variety of biochemical and physiologic criteria. Much of the current understanding of macrophage arachidonate metabolism stems from studies using different populations of murine peritoneal macrophages. These populations include both resident or resting macrophages and macrophages elicited by either an irritant, such as thioglycollate, or an immunologic challenge, such as heat-killed organisms of Corynebacterium or Myrobacterium. The diverse nature of the different cell populations is reflected in tbe different arachidonic acid metabolites tbese cells synthesize. Investigations using resting peritoneal macrophage have demonstrated that, in the unstimulated state, these cells release minimal metabolic products. If these resident macrophages are given an exogenous source of arachidonic acid in the absence of other stimuli, approximately 40% of the arachidonic acid is incorporated into phospholipids, while the remainder is metabolized to mono-HETEs and the stable analogue of PGI2, 6-Keto-PGF,,,. The metabolism of endogenous arachidonic acid (phospholipid boutxi) following a phagocytic challenge of zymosan or immune complexes was found to result in the formation of PGE,, 6-Keto-PGF,", and LTC4." In contrast, elicited peritoneal macrophages have a diminished capability to synthesize arachidonic acid metabolites, Mocrophages elicited with either an irritant or immunologic challenge incorporate more exogenous arachidonic acid and release significantly less metabolites. In addition, zymosan-treated-elicited macrophages convert endogenous arachidonic acid to only 10% of the metabolites formed by similarly treated resting cells.*^ A possible mechanism for the above observations may be due to an increase in the acylation of arachidonic acid or decrease in the deacylation by the activated macrophage populations. The absolute amounts of arachidonic acid metabolites released by various resting and elicited peritoneal macrophage populations in the presence and absence of a stimulus are shown in Table 1 .
In addition to the state of macrophage activation, the amount and variety of metabolites are dependent upon the particular stimulus under study. As discussed above, synthesis of aracbidonic acid metabolites by both the cyclooxygenase and lipoxygenase pathways can be observed when macrophages or monocytes are given a zymosan phagocytic challenge. Interestingly, phagocytosis itself does not appear to be directly responsible for product generation, since latex bead phagocytosis did not cause prostaglandin synthesis.^' The most important step in phagocytosis-induced arachidonate metabolism appears to be receptor-ligand interaction involving specific receptors." Macrophages treated with compounds that suppress lysosome-phagosome fusion and block phagocytosis still produced normal levels of PCEj when challenged with zymosan. A number of soluble stimuli that can induce membrane perturbation, independent of specific receptor interaction, also have been shown to stimulate arachidonic acid metabolism, including lipopolysaccharide (LPS), phorbot esters, and colchicine. As shown in Figure 2 , the selectivity of metabolite formation varies dramatically with the stimulus under study. The membrane perturbant LPS resulted in the synthesis of only cyclooxygenase products, while zymosan induced the synthesis of both cyclooxygenase and lipoxygenase-derived metabolites. It is important to reiterate that the metabolism of arachidonic acid by mononuclear phagocytic cells is dependent upon a multitude of independent factors: (1) the anatomic location of the macrophage, (2) the state of macrophage activation, (3) the stimulus under study, (4) whether the cells are adherent, and (5) the presence of free or membranebound arachidonic acid.
Regulation of Immune Cell Function by Metabolites of Arachidonic Acid
Experimental evidence supports the view that various metabolites of arachidonic acid can exert profound modulatory effects on cells involved in immuneinflammatory responses. The robust ability of certain macrophage populations to synthesize diverse arachidonic acid metabolites implicates these cells in the immunoregulation of immune reactions.^* It is well established that macrophages can synthesize rather large quantities of PGE2. The ability of PCE to promote local vasodilitation and edema'^ has led many clinicians to presume this prostaglandin to be proinflammatory; however, current experimental evidence suggests that PGE2 and PGI2 possess dramatic suppressive activity in macrophage-and lymphocyte-mediated reactions. In vitro. PGE2 has been shown to suppress a number of critical lymphocyte functions including B and T cell proliferation,^^^^^ natural killer cell activity,'^ and cellmediated cytotoxicity.^"^ With regard to the production of lymphocyte-derived soluble mediators, Gordon et al.**" and Bray et al."' have demonstrated that PGE2 can suppress lymphokine production, as monitored by macrophage migration inhibition. In addition, Baker and co-workers"-and Rappaport and Dodge'" have shown that PGE2 is efficacious in suppressing the production of interleukin-2 (IL-2). In the latter study, treatment of preparations with cyclooxygenase inhibitors was shown to augment the production of IL-2, thus providing support that endogenous PGE2 is involved in regulating tbe production of lymphocyte mediators. Prostaglandins also may exert an immunosuppressive effect by inducing the activity of suppressor T cells.'"' A supporting study suggests that PGE; inhibits mitogen-induced proliferation by inducing a short-lived radiosensitive suppressor T cell;"^ upon activation with PGE2, this lymphocyte population may suppress the proliferative response of the remaining lymphocytes.
It is becoming increasingly apparent that not only is the function and activity of lymphocytes regulated by prostaglandins, but the macrophage itself appears to be modulated by various arachidonic acid metabolites. Prostaglandin E2 has been shown to regulate macrophage oxygen metabolite production,'"' tumoricidal activity,""" and macrophage proliferation."" Of particular interest is tbe suppressive effect of PGE2 on the production of macrophage-and monocyte-derived signals necessary to activate lymphocytes. These studies include the inhibition of macrophage interleukin-1 (IL-1) production,^** as well as the suppression of lymphokine-induced macrophage membrane l-region associated (la) antigens."''^" The suppressive effect of PGE2 on macrophage la antigen expression appeared to possess a high degree of specificity since neither Fc receptor expression nor H-2K expression was altered. The in vivo suppression of la antigen expression would dramatically alter the antigen-presenting capability of macrophages and inhibit lymphocyte activation. We recently have demonstrated that IL-1, an important macrophage-derived signal witb profound effects on lymphocyte-mediated reactions, can be regulated by a self-induced inhibitor, PGE2.^*' As shown in Table 2 , PGE2 can suppress IL-1 production by LPS-stimulated macrophages in a dose-dependent manner. Furthermore, the cyclooxygenase inhibitor, indomethacin, demonstrated a dose-dependent augmentation in IL-1 production by LPS-stimulated macrophages. These studies suggest that endogenous PGE2 can serve as a mechanism to regulate the production of an important lymphocyte-activating factor.
Regulation of tn Vivo Macrophage-and Lymphocyte-dependent Reactions by Metabolites of Arachidonic Acid
Considering the large body of evidence showing that both macrophages and lymphocytes are targets for the regulatory effects of arachidonic acid metabolites, it is not surprising that numerous in vivo models have demonstrated that the development of chronic inflammation can be altered by these metabolites. Animal models of adjuvant-induced arthritis,'^' pulmonary hypersensitivity granulomas," and autoimmune nephritis^* all have been demonstrated to be susceptible to PGE-mediated suppression. The initial impetus to study the therapeutic effect of prostaglandins stemmed from the observation that these biologically active lipids, with in vitro suppressive activity, commonly were found in inflammatory exudates. Prostaglandin E2 treatment first was shown to be effective in suppressing the macrophage-and lymphocyte-mediated reactions that result in the development of the polyarthritic response. In an extension of these early studies, investigations have shown that the polyarthritic response can be suppressed by the oral administration of a stable ' IL-1 was assayed using a thymocyte proliferation assay in the presence of dialyzed macrophdge supernatant and suboplinial doses of PHA.
PGE, analogue, 15-methy!-PGEi." The oral activity of this compound most likely resides in its stability due to the protection of the 15-hydroxyl group from the action of the J5-hydroxy-prostaglandin dehydrogenase. The stable analogue of PGEi also was found to be efficacious in the treatment of murine systemic lupus erythematosus-like syndrome."^' Both NZB/NZW mice and MRL/1 mice responded to prostaglandin therapy with a decrease in clinical nephritis and mortality. The therapeutic activity of PGE compounds in tbese animals is most likely due to the preservation of cell-mediated immunity by dictating the appropriate number of T and B cells, since diminished T-lymphocyte populations and increased B-lymphocyte functions are an early index of this disease. Additional studies have demonstrated the ability of PGE to suppress the normal progression of the nephritic response in animal whose disease was established at the onset of treatment."^"^ Recent studies have examined the in vivo activity of prostaglandins on the development of foreign-body-and delayed-type hypersensitivity granulomatous inflammation. The delayed-type hypersensitivity granuloma involves a highly active T-lymphocyte-mediated lesion, whose development and regulation is controlled by macrophage-lymphocyte interactions, while the foreign body reaction is less vigorous and does not involve T ceil sensitization. Investigations have demonstrated that prostaglandins can alter the delayed-type hypersensitivity, but not the foreign-body response." In this study, PGE treatment was shown to suppress the elicitation of the granulomatous response and inhibit the induction of sensitized lymphocytes, whereas PGF^., augmented the elicitation phase of the response. To further elucidate the modeof PGE-induced suppression of the delayed- type hypt^rsensitivity lesion, the kinetics of the ap-[jcarance of la-positive macrophages in developing lesions was studied. Proslaglandin E treatment dramatirally suppressed granuloma macrophage la expression throughout the study period,^" at times by as much as 60%. On the contrary, PGF2,,, was shown to enhance granuloma macrophage la antigen expression during the early phase of granuloma development. The alteration in the percentage of ia positive granuloma macrophages was shown to parallel the degree of cellular infiltrate. Neither PGF^., nor PCE had an effecl on the low levels of la antigen being expressed on the macrophages recovered from the foreign-body lesions. These observations may prove to be very important in the control of noninfectious granulomatous inflammation, since la antigen expression by macrophages is a critical signal for antigen presentation and T-iymphocyte proliferation.
Summary
Numerous investigations support the theory that arachidonic acid metabolites play a critical role in dictating the progression of chronic immune reactions. With regard to macrophage-mediated inflammatory responses, enzymatic oxygenation of arachidonic acid via the lipoxygenase or cyclooxygenase pathway can result in the production of compounds that may potentiate or suppress the inflammatory lesion. We recently have presented data demonstrating that lipoxygenase derived leukotriene B4 and C4 can induce Ihe release of IL-1 by macrophages, while PGEj and PGIj can suppress the production of IL-1,-'*' Macrophages are central to the induction of immune responses and the progression of chronic inflammatory reactions. Therefore, an understanding of th<> role that macrophage-derived arachidonic acid metabolites play in the initiation, maintenance, and resolution of chronic immune responses is essential. As shown in Figure 3 , there are a number of chemical signals that occur between macrophages and lymphocytes that are critical for immune cell communication. The investigations described above have demonstrated that the macrophage may regulate the production and expression of any or all of these signals, such that the inflammatory response is potentiated, sustained, suppressed, or resolved. A better comprehension of the activity of these potent arachidonate derivatives will undoubtedly aid in the therapeutic manipulation of inflammatory disease.
